MedTrace Logo

An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting

NCT06359535 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-04-11

No results posted yet for this study

Summary

This study analyzed the efficacy and safety results of HSK21542 injection for the prevention of postoperative nausea and vomiting in a multicentre, randomized, double-blind, placebo-controlled dose-exploration study, as well as the real-world clinical routine use of troisisone and other (not limited to other setron drugs) for the prevention of postoperative nausea and vomiting and related adverse reaction treatment data. It was transformed into an effect indicator, and the possible costs involved in the study were analyzed, reasonable price parameters of HSK21542 injection were set, and the economic value of HSK21542 was explored.

Conditions

  • Nausea and Vomiting, Postoperative

Interventions

DRUG

HSK21542

This study is an economic study and does not interfere with patients' medical treatment.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Mengchang Yang

    lead OTHER

Principal Investigators

  • Mengchang Yang, Doctor · Prinipal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2024-11-06
Completion
2024-11-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359535 on ClinicalTrials.gov